Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), which accounts for 30鈥 40% of adult NHL with 27,650 estimated new cases diagnosed in the United States in 2016. DLBCL is defined as a B-cell neoplasm with a diffuse growth pattern of large tumor ...
CONCLUSIONS: Measurement of the expression of six genes is sufficient to predict overall survival in diffuse large-B-cell lymphoma. 展开 关键词: Gene Expression Lymphoma B-Cell Lymphoma Large-Cell Diffuse 基因表达 淋巴瘤 B细胞 淋巴瘤 大细胞 弥漫型 被引量: 849 年份: 2004 ...
Introduction: Multiple conflicting prognostic markers have been proposed for R‐CHOP treated diffuse large B‐cell lymphoma (DLBCL) cases. Aggressive behaviour has been shown to be associated with ABC‐like phenotype, Double Hit (DH) or Double Expression (DE) phenotype, CD5 expression and other ...
Effect of alternative splicing (AS) on diffuse large B-cell lymphoma (DLBCL) pathogenesis and survival has not been systematically addressed. Here, we compared differentially expressed genes and exons in association with survival after chemoimmunotherapy, and between germinal center B-cell like (GCB) ...
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease whose prognosis is associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative, multi-omic analyses had led to identifying overlapping genetic DLBCL subtyp
Over-expression of CXCR4 has been identified in haematological tumours, but data concerning the role of this receptor in diffuse large B cell lymphoma (DLBCL) are lacking. CXCR4 is a marker of poor prognosis in various neoplasms, correlating with metastatic disease and decreased survival of ...
Objective: To illustrate the effect and mechanism of ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that inhibits diffuse large B-cell lymphoma (DLBCL) cell survival. Methods: DLBCL cell lines SUDHL-10 and HBL-1 were treated with ibrutinib at different concentrations. A MTT assay was ...
Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Leukemia, 21 (2007...
Diffuse large B-cell lymphoma is the most commonly diagnosed subtype of lymphoma but represents a heterogeneous group of diseases with specific clinicopathological and immunophenotypical features, molecular pathogenesis and response to treatment. This review focus on DLBCL specific types/subtypes with emphas...